Morepen Laboratories Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹570.13 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.62 per cent from ₹484.72 crore. This corresponds to a year-on-year *(YoY) growth of 34.07 per cent.
Operating Profit
Operating Profit stands at ₹82.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 237.59 per cent from ₹24.45 crore. This corresponds to a year-on-year *(YoY) growth of 241.50 per cent.
PBDT
PBDT stands at ₹82.88 crore, reflecting a quarter-on-quarter *(QoQ) increase of 185.40 per cent from ₹29.04 crore. This corresponds to a year-on-year *(YoY) growth of 237.60 per cent.
Profit Before Tax
Profit Before Tax stands at ₹74.53 crore, reflecting a quarter-on-quarter *(QoQ) increase of 220.01 per cent from ₹23.29 crore. This corresponds to a year-on-year *(YoY) growth of 380.22 per cent.
Net Profit
Net Profit stands at ₹56.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 258.92 per cent from ₹15.70 crore. This represents a 393.87 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Morepen Laboratories Ltd Earnings
- YOY
- QOQ
Morepen Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Morepen Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Morepen Laboratories Ltd Financial Reports
Morepen Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Morepen Labs. | -7.98% | -8.45% | 18.78% | 104.13% | 182.87% | 100.08% |
| Jeena Sikho | -2.21% | -1.36% | -3.47% | -15.89% | -15.16% | -37.51% |
| SPARC | -4.08% | -6.28% | -4.66% | -21.12% | 64.71% | 30.81% |
| Orchid Pharma | -1.19% | -2.98% | -0.56% | -5.01% | 96.56% | 39.93% |
| FDC | 2.79% | -1.17% | -1.14% | -8.91% | 2.49% | -24.83% |
| Guj. Themis Bio. | 0.63% | -1.23% | 20.75% | 12.49% | 53.57% | 11.61% |
| Novartis India | -8.07% | 0.55% | 38.43% | 66.49% | 138.28% | 143.94% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Sushil Suri
WTD & Executive Director : Sanjay Suri
Independent Non Exe. Director : Praveen Kumar Dutt
Independent Non Exe. Director : Ranjit Khattar
Independent Non Exe. Director : Savita
Independent Non Exe. Director : Sharad Jain
Company Secretary : Vipul Kumar Srivastava